NCT07048665Active, not recruiting
Effectiveness of Trans-Arterial Chemo Embolization for Hepatocellular Carcinoma on Follow-Up CT Triphasic Liver
Source: ClinicalTrials.gov · Last updated 2 Jul 2025
Brief summary (registry, in English)
"HCC is a major challenge due to greater recurrence rates and variable treatment responses. TACE is widely used, but its success relies on accurate follow-up imaging. CT Triphasic Liver Imaging plays a vital role in assessing treatment response, guiding clinical decisions, and improving patient outcomes. The purpose of this study is to investigate the relationship between response of treatment, gender, age, and the cause of HCC. The purpose of the study is to evaluate how well TACE (trans-arterial chemoembolization) works for patients with HCC.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 60 (actual)
- First submitted
- 24 Jun 2025
- Start date
- 17 Mar 2025
- Primary completion date
- 30 Aug 2025
- Lead sponsor
- Superior University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07048665
What you commit to
- Study type: Observational
- Participants enrolled: 60
- From 17 Mar 2025 to the primary completion date, 30 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a history of severe comorbidities that might interfere with treatment response evaluation
Other
- Patients with incomplete or missing medical records and imaging studies.
- Patients who were contraindicated for CT scans at the time of follow-up.
- Patients that are contradicted with CT scan.
- Patient who underwent TACE more than four years before the study period.
Who the study is looking for
- Both Male and Female.
- Patients diagnosed with HCC who underwent TACE.
- Patients with no portal vein tumor thrombus (PVTT) or no extra Extrahepatic Metastases at the time of initial TACE treatment.
- Patients who underwent TACE within last your years from the study start date.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| AYK Hospital Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.